July 2017: We have reviewed the evidence and made new recommendations on treating Parkinson's disease symptoms, deep brain stimulation, monitoring and managing impulse control disorders, and palliative care. These recommendations are marked .
We have also made some changes without an evidence review:
changes made to clarify the action of a recommendation
the timeframe for referral was removed because it was not evidence based.
These recommendations are marked [2006, amended 2017].
Minor changes since publication
May 2022: We added a link to NICE's guideline on medicines associated with dependence or withdrawal symptoms in section 1.5.
March 2022: The heading above recommendations 1.5.4 and 1.5.5 was amended to clarify that this section covers both restless leg syndrome and rapid eye movement sleep behaviour disorder, and the abbreviation RBD was written out in full for clarity.
December 2020: We added advice for women who are pregnant or who are planning a pregnancy to recommendations 1.5.2 and 1.5.3, in line with the MHRA safety advice on modafinil.
September 2020: We linked to the NICE guideline on supporting adult carers in recommendation 1.1.4 and incorporated footnotes into the recommendations in line with accessibility requirements.
October 2019: Information was added to reflect a change in marketing authorisation status for botulinum neurotoxin type A preparations.